Cheema Abdullah A, Cheema Haider R
Ophthalmology, Royal Glamorgan Hospital, Cardiff, GBR.
Ophthalmology, Royal Berkshire Hospital, Reading, GBR.
Cureus. 2024 Jan 21;16(1):e52676. doi: 10.7759/cureus.52676. eCollection 2024 Jan.
Diabetic macular edema (DME) is a major cause of vision impairment in diabetic individuals, characterized by fluid accumulation in the macula due to a breakdown of the blood-retinal barrier (BRB). This review article explores the role of anti-vascular endothelial growth factor (anti-VEGF) therapies in the management of DME. Anti-VEGF treatments, including ranibizumab, bevacizumab, and aflibercept, have revolutionized DME management by targeting VEGF, a key mediator in DME pathogenesis. We critically examined the efficacy of these therapies in reducing macular edema and improving visual acuity, assessed their safety and tolerability, and explored the variability in treatment response. The review highlights the latest advancements and future directions in anti-VEGF therapy, including novel drug delivery systems and emerging treatment paradigms. By providing a comprehensive overview of current anti-VEGF therapies, this review seeks to inform clinical practice, guide future research, and contribute to improved patient outcomes in DME management.
糖尿病性黄斑水肿（DME）是糖尿病患者视力损害的主要原因，其特征是由于血视网膜屏障（BRB）破坏导致黄斑区积液。这篇综述文章探讨了抗血管内皮生长因子（anti-VEGF）疗法在DME治疗中的作用。抗VEGF治疗，包括雷珠单抗、贝伐单抗和阿柏西普，通过靶向VEGF（DME发病机制中的关键介质）彻底改变了DME的治疗方式。我们严格审查了这些疗法在减轻黄斑水肿和提高视力方面的疗效，评估了它们的安全性和耐受性，并探讨了治疗反应的变异性。该综述强调了抗VEGF治疗的最新进展和未来方向，包括新型药物递送系统和新兴治疗模式。通过全面概述当前的抗VEGF疗法，本综述旨在为临床实践提供信息，指导未来研究，并有助于改善DME治疗中的患者预后。
